Scarica l'app Stockscreener
8.00
6.67%
0.50
Dopo l'orario di chiusura:
7.80
-0.20
-2.50%
Precedente Chiudi:
$7.50
Aprire:
$7.6
Volume 24 ore:
109.77K
Relative Volume:
1.59
Capitalizzazione di mercato:
$77.06M
Reddito:
$1.15M
Utile/perdita netta:
$-46.90M
Rapporto P/E:
-2.7209
EPS:
-2.9402
Flusso di cassa netto:
$865.00K
1 W Prestazione:
+13.48%
1M Prestazione:
-9.19%
6M Prestazione:
-42.28%
1 anno Prestazione:
-6.43%
Intervallo 1D:
$7.60
$8.18
Intervallo di 1 settimana:
$6.87
$8.29
Portata 52W:
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
8.00 | 72.24M | 1.15M | -46.90M | 865.00K | -2.9402 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
MSN Money - MSN
Seres Therapeutics 1Q 2026: Revenue $358K, EPS $(2.08) — 10-Q Summary - TradingView
Seres Therapeutics (NASDAQ: MCRB) Q1 2026 loss and going-concern risk - Stock Titan
Seres Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics (Nasdaq: MCRB) Q1 2026 results and cash runway - Stock Titan
Seres awaits SER-155 data in weeks with cash through Q3 - Stock Titan
Seres presents preclinical data on IBD drug candidate SER-603 - Investing.com UK
Seres presents preclinical data on IBD drug candidate SER-603 By Investing.com - Investing.com South Africa
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease - The Manila Times
Experimental IBD microbiome therapy earns DDW poster honor - Stock Titan
Seres Therapeutics Presents Preclinical Data at Digestive - GlobeNewswire
MCRB stock declines as Seres Therapeutics pauses SER-155 phase 2 study and shrinks headcount by 30% - MSN
Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Equity plan and director votes in Seres Therapeutics (NASDAQ: MCRB) 2026 proxy - Stock Titan
Microbiome Therapeutics Market is Going to Booming Growth - openPR.com
Chardan Capital Downgrades Seres Therapeutics (MCRB) - MSN
MCRB Price Today: Seres Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics (MCRB) Presents Key Data at ESCMID Congress - GuruFocus
Seres Therapeutics (MCRB) Showcases Research at ESCMID 2026 Cong - GuruFocus
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 - The Manila Times
Seres spotlights microbiome data for transplant patients at ESCMID - Stock Titan
Aug Catalysts: Is Seres Therapeutics Inc impacted by rising rates2026 AllTime Highs & Safe Entry Trade Signal Reports - baoquankhu1.vn
Seres Therapeutics Stock Price Drops Below 50-Day Average - National Today
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Will Seres Therapeutics Inc benefit from green energy policies2026 Chart Watch & High Accuracy Trade Alerts - baoquankhu1.vn
Is Seres Therapeutics (MCRB) Stock a Buy Now | Price at $8.51, Down 2.34%Volume Leaders - Newser
Seres Therapeutics to Present at CARB-X Investor Day - Bitget
Seres brings CARB-X-backed ICU infection therapy to Munich event - Stock Titan
Aug Ideas: Should I invest in Seres Therapeutics Inc before earnings2026 Setups & Low Drawdown Trading Strategies - baoquankhu1.vn
VIX Spike: Does Seres Therapeutics Inc have declining or rising EPSWeekly Stock Analysis & Daily Entry Point Alerts - baoquankhu1.vn
MCRB SEC FilingsSeres Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
What are the biggest risks for Seres Therapeutics (MCRB) Stock | Price at $9.27, Up 4.63%Capital Preservation - Cổng thông tin điện tử tỉnh Lào Cai
Market Fear: Can Seres Therapeutics Inc weather a recessionDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
Market Rankings: Is Seres Therapeutics Inc in a bullish channelTrade Volume Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026 - MSN
Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - msn.com
If You Invested $1,000 in Seres Therapeutics Inc (MCRB) - Stock Titan
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):